Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 14/20 | 0.40 |
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4800782 | 0.77 | GPR119 (0.33) | DPP4 | |
| SCHEMBL4799173 | 0.71 | CNR1 (0.42) | KDM1ACTBP2 | |
| SCHEMBL2817469 | 0.68 | GRIN2B (0.36) | — | |
| SCHEMBL2819757 | 0.63 | — | — | |
| SCHEMBL4799890 | 0.63 | ARG1 (0.42) | HTTCTBP2 | |
| SCHEMBL443388 | 0.61 | — | — | |
| SCHEMBL408012 | 0.61 | S1PR5 (0.63) | DPP4DPP8 | |
| SCHEMBL1818900 | 0.61 | SLC6A2 (0.46) | HTTCTBP2 | |
| SCHEMBL27999407 | 0.61 | SLC6A2 (0.46) | HTTCTBP2 | |
| SCHEMBL10275551 | 0.60 | CTBP2 (0.56) | HTTCTBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262070-A1 | Pharmaceutically Active Tetrahydro-Pyrrolizinone Compounds | BAUMANN KARL | 2008-10-23 | — | — | US | disclosed |
| EP-1937685-A1 | TETRAHYDRO-PYRROLIZINONE COMPOUNDS AS LFA-I MEDIATORS | Novartis AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039286-A1 | TETRAHYDRO-PYRROLIZINONE COMPOUNDS AS LFA-I MEDIATORS | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262070-A1 | Pharmaceutically Active Tetrahydro-Pyrrolizinone Compounds | VCAM1, ICAM1, EPCAM | KDM1A 3314/4885DPP4 1178/4885DPP8 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.